Office of Cancer Complementary and Alternative Medicine, Bethesda, MD 20892, USA.
Integr Cancer Ther. 2013 Sep;12(5):385-92. doi: 10.1177/1534735412473641. Epub 2013 Jan 25.
The National Cancer Institute (NCI) Best Case Series (BCS) Program provides an independent review of medical records, imaging, and pathology of cancer patients treated with unconventional therapies. The goal of the NCI BCS Program is to identify preliminary evidence of tumor regression and assess whether there is sufficient evidence to move forward with NCI-initiated research. The objective was to review case reports submitted by 4 practitioners from India who used ayurvedic and homeopathic therapies to treat cancer.
Retrospective review of case reports of 4 practitioners from India who used ayurvedic and homeopathic therapies to treat cancer.
A total of 68 cases were submitted to the NCI BCS Program. Fifty-one percent of the cases represented homeopathy and 49% ayurveda. Of the 68 cases, 32 (47%) of the cases were collectively designated as "persuasive" (P) or "supportive"(S), and 36 (53%) as "not evaluable." Forty-one (60%) patients did not have any prior conventional treatment.
The challenge for submitters rests in their ability to supply sufficient documentation for the NCI BCS Program. The NCI BCS Program represents a unique avenue for the rigorous evaluation of "best cases" to identify complementary and alternative medicine modalities that are promising for prospective preclinical evaluation or prospective research.
美国国家癌症研究所（NCI）最佳案例系列（BCS）计划对接受非常规疗法治疗的癌症患者的病历、影像和病理进行独立审查。NCI BCS 计划的目标是确定肿瘤消退的初步证据，并评估是否有足够的证据启动 NCI 发起的研究。目的是审查来自印度的 4 名从业者提交的使用顺势疗法和顺势疗法治疗癌症的病例报告。
对来自印度的 4 名从业者使用顺势疗法和顺势疗法治疗癌症的病例报告进行回顾性审查。
共有 68 例病例提交给 NCI BCS 计划。51%的病例为顺势疗法，49%为顺势疗法。在 68 例病例中，32 例（47%）被集体指定为“有说服力”（P）或“支持”（S），36 例（53%）为“不可评估”。41 例（60%）患者没有任何先前的常规治疗。
提交者的挑战在于他们是否有能力为 NCI BCS 计划提供足够的文件。NCI BCS 计划代表了严格评估“最佳案例”的独特途径，以确定有前途的临床前评估或前瞻性研究的补充和替代医学模式。
